And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release.

NEW YORK (WPIX) – The U.S ... The nasal spray can be given to people who haven’t seen improvements in their depression after taking at least two oral medications, according to Johnson ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Johnson & Johnson has announced the FDA’s approval of a first-of ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is ... about $780 million for its maker, Johnson & Johnson.

Here’s where they ended ... Program.” The nasal spray targets glutamate, the most abundant excitatory neurotransmitter in the brain, according to Johnson & Johnson. If you are interested ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval ... this approval in Johnson & Johnson’s news ...

Health care giantJohnson & Johnson said on Wednesday the US Food and Drug Administration (FDA) has approved its drug ... felt primarily within the company's medical technology unit, which makes ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY TM ... Learn more about this approval in ...